Why West Pharmaceutical Services, Inc.’s (WST) Stock Is Down 5.17%
As of Friday, July 24, West Pharmaceutical Services, Inc.’s WST share price has dipped by 5.17%, which has investors questioning if this is right time to buy.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Michael Rose
Michael Rose
Michael Rose
| Share Statistics | WST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $24,896.8 | $3,076.5 | 88% |
|
| Shares Out (Mil) | 71.3 | 96.5 | 55% |
|
| Institutional Ownership | 99.4% | 90.0% | 88% |
|
| Float (Mil) | 69.9 | 71.5 | 54% |
|
| Beta | 1.16 | 1.22 | 69% |
|
| Avg Daily Volume (000s) | 471 | 710 | 57% |
|
| Price Change (52-week) |
43.2% | 89.4% | 76% |
|
| Growth | WST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.4% | 7.8% | 47% |
|
| Net Income (5yr) | 7.4% | (13.7%) | 51% |
|
| EPS (5yr) | 8.2% | 0.7% | 43 |
|
| Dividends (5yr) | 5.5% | 0.0% | 77% |
|
| Cash Flow (5yr) | 12.1% | (15.0%) | 71% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 16 | 16 | |
| Current EPS | $2.190 | $8.959 | $9.965 | |
| Month Ago EPS | $2.126 | $8.616 | $9.620 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $2.134 | $8.620 | $9.553 | |
| Year/Year Chg | 1.9% | 31.9% | 67.0% | |
| Financials | WST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,327 | $800 | 68% |
|
| Net Income (TTM) (Mil) | $565 | ($31) | 80% |
|
| EPS (TTM) | $7.862 | ($0.300) | 92% |
|
| Operating Cash Flow (TTM) (Mil) | $662 | $47 | 75% |
|
| Net Cash Flow (TTM) (Mil) | ($74) | $5 | 16% |
|
| Long-Term Debt (Q1) (Mil) | $294 | $270 | 53% |
|
| Enterprise Value (Q1) (Mil) | $22,978 | $3,795 | 85% |
|
| Valuation | WST | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.33 | 3.68 | 87% |
|
| P/E | 45.3 | 39.8 | 82% |
|
| Dividend Yield | 0.2% | 0.0% | 60% |
|
| PEG (5yr hist) | 5.5 | 5.5 | 89% |
|
| Ratios | WST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 36.8% | 47.7% | 45% |
|
| Net Margin | 17.0% | (3.2%) | 75% |
|
| ROA | 14.1% | (4.3%) | 93% |
|
| ROE | 19.1% | (7.9%) | 78% |
|
| Liabilities to Assets | 26.6% | 42.0% | 18% |
|
| F-Score | 9 | 5 | 98% |
|
West Pharmaceutical Services, Inc. did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors